Prosecution Insights
Prosecution Insights
8 pending office actions • 7 art units • 7 examiners • 0 of 8 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (25%) |
| Double-patenting + other | 2 (25%) |
| Multi-statute (no §101) | 4 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEVENS, MARK V | 2 | 65.4% | +42.0% |
| ZAHORIK, AMANDA MARY | 1 | 56.3% | +49.1% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.3% |
| GZYBOWSKI, MICHAEL STANLEY | 1 | 67.1% | +53.4% |
| WILSON, MICHAEL C | 1 | 41.4% | +17.5% |
| BABSON, NICOLE PLOURDE | 1 | 46.6% | +33.0% |
| WEIDNER, ADAM M | 1 | 63.6% | +34.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17598154 | COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY | WILSON, MICHAEL C | 215d overdue |
| 17045137 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS | BABSON, NICOLE PLOURDE | 23d overdue |
| 18276010 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING MPS VI DISEASE | ZAHORIK, AMANDA MARY | 5d overdue |
| 18274125 | COMPOSITIONS, DEVICES AND METHODS FOR INDUCING ANTIGEN-SPECIFIC IMMUNE TOLERANCE | STEVENS, MARK V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17598154 | COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY | WILSON, MICHAEL C | 215d overdue |
| 17784972 | COMPOUNDS, POLYMERS, DEVICES, AND USES THEREOF | CHANDRAKUMAR, NIZAL S | 29d overdue |
| 17045137 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS | BABSON, NICOLE PLOURDE | 23d overdue |
| 18276010 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING MPS VI DISEASE | ZAHORIK, AMANDA MARY | 5d overdue |
| 17764096 | METHODS OF EVALUATING POLYPEPTIDE-MODIFIED POLYMERS IN COMPOSITIONS | GZYBOWSKI, MICHAEL STANLEY | 9d |
| 18274125 | COMPOSITIONS, DEVICES AND METHODS FOR INDUCING ANTIGEN-SPECIFIC IMMUNE TOLERANCE | STEVENS, MARK V | — |
| 18019664 | HETEROARYL AND HETEROCYCLYL COMPOUNDS | STEVENS, MARK V | — |
| 16651892 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | WEIDNER, ADAM M | — |
| Art Unit | Apps |
|---|---|
| 1613 | 2 |
| 1636 | 1 |
| 1625 | 1 |
| 1798 | 1 |
| 1638 | 1 |
| 1619 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18276010 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING MPS VI DISEASE | ZAHORIK, AMANDA MARY | 1636 | §103§112 | Non-Final OA | 5d overdue | Pending | Aug 04, 2023 |
| 18274125 | COMPOSITIONS, DEVICES AND METHODS FOR INDUCING ANTIGEN-SPECIFIC IMMUNE TOLERANCE | STEVENS, MARK V | 1613 | §103§112 | Non-Final OA | — | Pending | Jul 25, 2023 |
| 18019664 | HETEROARYL AND HETEROCYCLYL COMPOUNDS | STEVENS, MARK V | 1613 | §102§103§112DP | Non-Final OA | — | Pending | Feb 03, 2023 |
| 17784972 | COMPOUNDS, POLYMERS, DEVICES, AND USES THEREOF | CHANDRAKUMAR, NIZAL S | 1625 | §103DP | Non-Final OA | 29d overdue | Pending | Jun 13, 2022 |
| 17764096 | METHODS OF EVALUATING POLYPEPTIDE-MODIFIED POLYMERS IN COMPOSITIONS | GZYBOWSKI, MICHAEL STANLEY | 1798 | §103 | Non-Final OA | 9d | Pending | Mar 25, 2022 |
| 17598154 | COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY | WILSON, MICHAEL C | 1638 | §103§112 | Non-Final OA | 215d overdue | Pending | Sep 24, 2021 |
| 17045137 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS | BABSON, NICOLE PLOURDE | 1619 | §103§112 | Final Rejection | 23d overdue | Pending | Oct 02, 2020 |
| 16651892 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | WEIDNER, ADAM M | 1675 | §103Other | Final Rejection | — | Pending | Mar 27, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial